Patented biomarker for cardiac injury. 

Patented biomarker for cardiac injury. 

Tag: Ambulance

cMyC is superior to hs-cTnT to rule-out chest pain patients with final AMI diagnose with blood-samples done at time of ambulance pickup.
cMyC is more abundant than Troponin and provides discriminatory power comparable to hs-cTnT/I for the diagnosis of AMI in all-comers, and identifies a greater proportion of patients with AMI in very early presenters. A standout feature is cMyC’s ability to more effectively triage patients. This distinction is likely related to the documented greater abundance and more rapid release profile of cMyC. If used on a POCT platform, cMyC could significantly improve the early triage of patients with suspected AMI.